BERLIN, GERMANY — An investigational RNA interference (RNAi) agent that reduces levels of circulating antithrombin promotes clotting function in people with hemophilia A or B [1]. By depleting ...

Antithrombin deficiency, whether inherited or acquired, poses a significant risk factor for venous thromboembolism (VTE) by impairing the natural regulation of coagulation. As a critical plasma ...

BOSTON, Mass., July 16, 2009– Data presented at the annual meeting of the International Society on Thrombosis and Haemostasis (ISTH) in Boston show that ATryn® (Antithrombin [Recombinant]) safely ...

INNOVANCE Antithrombin assay is a cutting-edge, ready-to-use chromogenic reagent for the automated determination of antithrombin (AT) activity. It is highly accurate even at low activity levels and ...

Fitusiran antithrombin-based dose regimen targeting 15%-35% of antithrombin activity demonstrated favorable safety profile in male participants aged ≥ 12 years with severe hemophilia A or B, with or ...